Phagocytosis checkpoints as new targets for cancer immunotherapy

• Published in: Nature reviews. Cancer Vol. 19; no. 10; pp. 568 - 586
• Main Authors: Feng, Mingye, Jiang, Wen, Kim, Betty Y. S., Zhang, Cheng Cheng, Fu, Yang-Xin, Weissman, Irving L.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.10.2019; Nature Publishing Group
• Subjects: 631/67/580; 631/80/313/1727; 692/420/2780/262; 692/699/67/1059/2325; Adaptive Immunity; Animals; Antimitotic agents; Antineoplastic agents; Apoptosis; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer immunotherapy; Cancer Research; CD47 Antigen - metabolism; Humans; Immune checkpoint; Immune clearance; Immune response; Immunity, Innate; Immunosurveillance; Immunotherapy; Immunotherapy - methods; Licensing, certification and accreditation; Lymphocytes - cytology; Macrophages; Metastases; Mice; Neoplasm Metastasis; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - therapy; Phagocytes; Phagocytosis; Review Article; SHPS-1 protein; Signal Transduction; Tumor Escape; Tumors; United States
• ISSN: 1474-175X; 1474-1768; 1474-1768
• DOI: 10.1038/s41568-019-0183-z

Cancer immunotherapies targeting adaptive immune checkpoints have substantially improved patient outcomes across multiple metastatic and treatment-refractory cancer types. However, emerging studies have demonstrated that innate immune checkpoints, which interfere with the detection and clearance of malignant cells through phagocytosis and suppress innate immune sensing, also have a key role in tumour-mediated immune escape and might, therefore, be potential targets for cancer immunotherapy. Indeed, preclinical studies and early clinical data have established the promise of targeting phagocytosis checkpoints, such as the CD47–signal-regulatory protein α (SIRPα) axis, either alone or in combination with other cancer therapies. In this Review, we highlight the current understanding of how cancer cells evade the immune system by disrupting phagocytic clearance and the effect of phagocytosis checkpoint blockade on induction of antitumour immune responses. Given the role of innate immune cells in priming adaptive immune responses, an improved understanding of the tumour-intrinsic processes that inhibit essential immune surveillance processes, such as phagocytosis and innate immune sensing, could pave the way for the development of highly effective combination immunotherapy strategies that modulate both innate and adaptive antitumour immune responses. Innate immune checkpoints, including those regulating tumour detection and phagocytosis, have emerged as potential cancer immunotherapy targets. This Review discusses the role of phagocytosis checkpoints in cancer immune evasion, highlighting the preclinical and early clinical evidence supporting phagocytosis checkpoint blockade.